Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466280 | 0.88 | EGFR (0.69) | ERBB2EGFR | |
| SCHEMBL466281 | 0.87 | EGFR (0.66) | ERBB2EGFR | |
| SCHEMBL466189 | 0.87 | EGFR (0.70) | ERBB2EGFR | |
| SCHEMBL466103 | 0.86 | EGFR (0.84) | ERBB2EGFR | |
| SCHEMBL466260 | 0.85 | ERBB2 (0.66) | ERBB2EGFR | |
| SCHEMBL466271 | 0.85 | EGFR (0.67) | ERBB2EGFR | |
| SCHEMBL466210 | 0.84 | EGFR (0.73) | ERBB2EGFR | |
| SCHEMBL466238 | 0.83 | EGFR (0.74) | ERBB2EGFR | |
| SCHEMBL466230 | 0.83 | EGFR (0.65) | ERBB2EGFR | |
| SCHEMBL6023184 | 0.83 | ERBB2 (0.68) | ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569937-B1 | C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL MYERS SQUIBB CO (US) | 2011-11-23 | — | — | EP | claimed |
| US-20110086850-A1 | RADIOSENSITIZATION OF TUMORS WITH INDAZOLPYRROLOTRIAZINES FOR RADIOTHERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-04-14 | — | — | US | claimed |
| WO-2009126311-A1 | RADIOSENSITIZATION OF TUMORS WITH INDAZOLPYRROLOTRIAZINES FOR RADIOTHERAPY | THE UNIVERSITY OF TEXAS, M.D. ANDERSON CANCER CENTER (US) | 2009-10-15 | — | — | WO | claimed |
| US-6916815-B2 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-12 | — | — | US | claimed |
| US-20040142931-A1 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | claimed |
| EP-2405941-A1 | COMBINATION OF AN INDAZOLYLAMINOPYRROLOTRIAZINE AND TAXANE FOR CANCER TREATMENT | Ambit Biosciences Corporation (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-1569937-B1 | C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL MYERS SQUIBB CO (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110086850-A1 | RADIOSENSITIZATION OF TUMORS WITH INDAZOLPYRROLOTRIAZINES FOR RADIOTHERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2010105016-A1 | COMBINATION OF AN INDAZOLYLAMINOPYRROLOTRIAZINE AND TAXANE FOR CANCER TREATMENT | AMBIT BIOSCIENCES CORP. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2009126311-A1 | RADIOSENSITIZATION OF TUMORS WITH INDAZOLPYRROLOTRIAZINES FOR RADIOTHERAPY | THE UNIVERSITY OF TEXAS, M.D. ANDERSON CANCER CENTER (US) | 2009-10-15 | — | — | WO | disclosed |
| US-7148220-B2 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-12 | — | — | US | disclosed |
| US-7102001-B2 | Process for preparing pyrrolotriazine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060014741-A1 | Synthetic process, and crystalline forms of a pyrrolotriazine compound | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
| US-20050222153-A1 | C-6 modified indazolylpyrrolotriazines | VITE GREGORY D | 2005-10-06 | — | — | US | disclosed |
| US-20050209454-A1 | Synthetic process | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-22 | — | — | US | disclosed |
| US-6916815-B2 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040209930-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | disclosed |
| US-20040142931-A1 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209454-A1 | Synthetic process | ERBB2, EGFR, ERBB4 | ERBB2 1/4885EGFR 2/4885 |
| US-20050222153-A1 | C-6 modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | ERBB2 1/4885EGFR 3/4885 |
| US-20060014741-A1 | Synthetic process, and crystalline forms of a pyrrolotriazine compound | ERBB2, FGFR1, ERBB4 | ERBB2 1/4885EGFR 4/4885 |
| US-20110086850-A1 | RADIOSENSITIZATION OF TUMORS WITH INDAZOLPYRROLOTRIAZINES FOR RADIOTHERAPY | IDH3A, TPT1, IDO1 | ERBB2 4345/4885EGFR 4184/4885 |
| US-20040209930-A1 | Synergistic methods and compositions for treating cancer | IGF1R, CHEK2, MCL1 | ERBB2 8/4885EGFR 6/4885 |
| US-20040142931-A1 | C-6 modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | ERBB2 1/4885EGFR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.